How Wegovy Helps You Lose Weight: the Science Behind It

The biology: why some people find eating less becomes easier on Wegovy

After you eat, your gut releases GLP-1, a hormone that travels to the brain and the stomach. It tells the brain you're satisfied; it tells the stomach to slow down. In most people this signal is short-lived. Semaglutide (the molecule inside Wegovy) is a long-acting analogue of that same hormone, designed to stay active for around a week from a single injection. That sustained presence keeps the fullness signal running in a way a natural post-meal burst simply doesn't.

What people often notice first isn't dramatic weight loss; it's that the pull towards food changes. A portion they'd normally finish easily feels like enough earlier. Snacking between meals stops feeling necessary. This isn't willpower reprogrammed, it's a pharmacological shift in how appetite signals reach the brain. If you're curious about the detail, our page on how Wegovy helps with weight loss explains the mechanism in plain terms. The NHS medicines page for semaglutide describes this mechanism clearly and is worth reading alongside any consultation.

Gastric emptying also slows on Wegovy. Food moves from the stomach into the small intestine more gradually, which extends the physical sensation of fullness and flattens post-meal blood sugar spikes. For people who have always felt hungry again within an hour of eating, this aspect of the medicine is often the one that makes the most practical difference to their day.

None of this works in isolation. The medicine is licensed alongside a reduced-calorie diet and increased physical activity, because the biological change it creates works best when it isn't fighting against habits that were maintaining excess weight in the first place.

What the trial evidence shows, and where it has limits

The STEP 1 trial is the foundation. Around 1,961 adults with obesity or overweight and at least one weight-related condition took part, randomly assigned to semaglutide 2.4mg or placebo over 68 weeks. The semaglutide group lost an average of around 15% of starting body weight, compared with roughly 2.4% in the placebo group. That's meaningful, but it's an average across a population: some people lost more, some less.

The STEP programme as a whole looked at different populations (people with type 2 diabetes, people with cardiovascular disease) and results varied. Outcomes were consistently better in people without type 2 diabetes. Weight loss also slows and eventually plateaus; the medicine doesn't produce indefinite loss. And, critically, weight tends to return if treatment stops without sustained lifestyle change in place. If you're thinking about how to approach your diet and routine during treatment, our guide on making the most of Wegovy covers the practical side.

A newer, higher-strength formulation (the 7.2mg maintenance dose, approved by the MHRA in January 2026) produced around 20.7% average weight loss over 72 weeks in trials, narrowing the gap with tirzepatide. The Wegovy overview page has the full picture on available formulations and eligibility.

Side effects that matter when thinking about whether Wegovy is right for you

The most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, indigestion. These are typically most noticeable in the early weeks of treatment or after a dose increase, and for many people they settle within a fortnight. Staying well hydrated, eating smaller amounts more slowly, and avoiding rich or fatty meals in the first weeks can help.

Starting doses are low for exactly this reason, the escalation schedule gives your system time to adjust before reaching a maintenance dose. Keep the pen in the fridge door (alongside the milk or eggs) as a simple reminder that it's a once-weekly medicine, not a daily one, routines make compliance much easier than relying on memory alone.

Less common but more serious effects include acute pancreatitis, gallbladder problems and, in rare cases, allergic reactions. The MHRA issued a Drug Safety Update in January 2026 flagging severe, persistent abdominal pain (particularly pain that radiates to the back) as a reason to seek urgent medical help rather than wait. You can report any suspected side effects directly through the MHRA Yellow Card scheme. Wegovy is not recommended during pregnancy or breastfeeding, is not licensed for under-18s, and is not suitable for anyone trying to conceive, these are conversations for a prescriber, not for a product page.

There's a broader look at how semaglutide's mechanism compares across products in our semaglutide and weight loss section, if you're weighing up your options.

The decision about whether Wegovy suits you is a clinical one

Wegovy is licensed for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition (such as high blood pressure, high cholesterol or obstructive sleep apnoea). Lower thresholds can apply for some ethnic backgrounds under UK guidance. Meeting the licence criteria is the starting point, not the final answer: a prescriber also looks at your medical history, current medicines and any contraindications before deciding whether treatment is appropriate.

At nume, a GPhC-registered Independent Prescriber reviews your consultation personally, a real clinician reads your answers, not software. If approved, treatment is dispatched the same day (for orders placed before 12pm, Monday to Friday) and arrives free the next working day via tracked DPD delivery. Pricing context, including what's included in a single transparent figure, is set out on the Wegovy pricing page. Our clinical team profile has more on who oversees prescribing at nume.

For anyone comparing Wegovy with tirzepatide or other options, the weight loss treatments overview walks through the licensed options side by side. And if you want to understand the GLP-1 class more broadly, how semaglutides work gives a wider view of the mechanism.

If you're ready to find out whether Wegovy is clinically suitable for you, you're welcome to speak to our prescribers through a free consultation, no obligation, no upfront fee.

Start your free consultation with our prescribers